<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465827</url>
  </required_header>
  <id_info>
    <org_study_id>BispebjergH</org_study_id>
    <nct_id>NCT02465827</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Selective Blockade of the Saphenous and Obturator Nerves Following Total Knee Arthroplasty</brief_title>
  <official_title>Selective Blocks for Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to evaluate the efficacy of selective low volume ultrasound-guided
      blockades of the saphenous and obturator nerves on dynamic and rest pain 24-hours
      post-operatively for patients undergoing unilateral primary total knee arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A femoral nerve block is the recommended strategy in many surgical centers to supplement
      multimodal analgesic regime following total knee arthroplasty (TKA) (i.e. both for spinal and
      general anesthesia). However, a femoral nerve block will often result in quadriceps
      paralysis, and this will increase the risk for the patient to fall as long as the femoral
      block have effect. Thus, the search for sensory nerve blocks to stop pain after TKA is a very
      interesting topic. The saphenous nerve is a purely sensory nerve, and the posterior branch of
      the obturator nerve is a mixed nerve, where the motor component only affects part of the
      adductor major muscle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamic pain (pain upon movement) quantified as area-under-the-curve (AUC) 24-hours post-operatively</measure>
    <time_frame>24 hours</time_frame>
    <description>NRS 0-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain at rest quantified as area-under-the-curve (AUC) 24-hours post-operatively</measure>
    <time_frame>24 hours</time_frame>
    <description>NRS 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea and vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>NRS 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first mobilization</measure>
    <time_frame>24 hours</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in recovery and hospital</measure>
    <time_frame>72 hours</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinical complications</measure>
    <time_frame>72 hours</time_frame>
    <description>total number</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Knee Arthroplasty, Total</condition>
  <arm_group>
    <arm_group_label>Saphenous and obturator nerve block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of ropivacaine 0,75% for the obturator nerve block.
Ropivacaine 0.75% for nerve blockades for both nerves mentioned.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saphenous nerve block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.
Ropivacaine 0.75% for the saphenous nerve block and saline for the obturator nerve block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo nerve block</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 ml of isotonic saline for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.
Saline for nerve blockades for both nerves mentioned.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nerve block with ropivacaine</intervention_name>
    <description>Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with ropivacaine 0.75% for both nerve branches</description>
    <arm_group_label>Saphenous and obturator nerve block</arm_group_label>
    <other_name>Saphenous and obturator nerve block with ropivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nerve block with ropivacaine and with saline</intervention_name>
    <description>nerve blocks of the saphenous nerve with ropivacaine 0.75% and obturator nerve, posterior branch with saline</description>
    <arm_group_label>Saphenous nerve block</arm_group_label>
    <other_name>Saph block with ropivacaine and obtur block with saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nerve block with saline</intervention_name>
    <description>Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with saline for both nerve branches</description>
    <arm_group_label>Placebo nerve block</arm_group_label>
    <other_name>saphenous and obturator nerve block with saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. American Society of Anesthesiologists' physical classification I-III

          2. Age â‰¥ 18 years undergoing primary unilateral total knee arthroplasty

        Exclusion Criteria:

          1. Inability to cooperate

          2. Inability to speak and understand Danish

          3. Allergy to any drugs used in the study

          4. Drug or alcohol abuse

          5. Pregnancy or nursing

          6. Opioid abusers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Jens Borglum Neimann</investigator_full_name>
    <investigator_title>Ass professor, PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

